Physician profile
Kris D Bhat
NPI 1134124696
$3,870.16
in general payments reported to CMS, 2019-2025
22 companies · $1,163 in 2025
The $1,163 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $172 · 2020: $14.49 · 2021: $238 · 2022: $434 · 2023: $1,021 · 2024: $828 · 2025: $1,163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,912 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,912.20 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $631.32 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $518.46 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $491.00 | 2022-2025 | |
| Blueprint Medicines Corporation | $263.12 | 2023 | Ayvakit |
| Biocryst US Sales Co., LLC | $261.20 | 2022-2023 | Orladeyo |
| Takeda Pharmaceuticals U.S.A., INC. | $246.69 | 2024-2025 | Cuvitru, Takhzyro |
| Ars Pharmaceuticals Operations, INC. | $145.69 | 2025 | Neffy |
| Incyte Corporation | $139.24 | 2024-2025 | Opzelura |
| Abbvie INC. | $130.77 | 2023 | Rinvoq |
| Regeneron Healthcare Solutions, INC. | $128.99 | 2019-2023 | Dupixent |
| Grifols USA, LLC | $124.63 | 2023-2025 | Xembify |
| Sanofi-Aventis U.S. LLC | $122.40 | 2021-2024 | |
| Organon LLC | $107.73 | 2025 | Vtama |
| Cycle Pharmaceuticals INC | $95.45 | 2025 | Sajazir |
| Pfizer INC. | $79.52 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $78.63 | 2025 | Xolair |
| Phadia US INC. | $74.93 | 2022 | |
| Abbott Laboratories | $72.49 | 2022-2025 | Eterna |
| Octapharma USA, INC. | $55.49 | 2022 | |
| Kedrion Biopharma INC. | $45.01 | 2021 | |
| Optinose US, INC. | $38.28 | 2019-2024 | |
| Baxter Healthcare | $19.12 | 2023 | Hillrom - Vest System Model 105 Home Care |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kris Bhat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.